ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- ToolGen Inc. (K...
South Korean Biotech, ToolGen Leads the Development of Numerous Cutting-Edge Genome Editing Techniques
SEOUL, South Korea, April 18, 2023 /PRNewswire/ -- Until now, most of the major
breakthroughs in the CRISPR field have been led by US academics. Not anymore;
Toolgen, aSouth Korea-based biotech company, has reported three breakthrough
techniques in top-tier scientific journals.
